Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 957957, 9 pages
http://dx.doi.org/10.1155/2011/957957
Review Article

Camptothecin-Based Regimens for Treatment of Ewing Sarcoma: sPast Studies and Future Directions

Division of Pediatric Hematology/Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, MLC 7015, 3333 Burnet Avenue, Cincinnati, OH 45229, USA

Received 1 July 2010; Accepted 17 January 2011

Academic Editor: Irene Andrulis

Copyright © 2011 Lars Wagner. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [11 citations]

The following is the list of published articles that have cited the current article.

  • Gabriele Zoppoli, Marie Regairaz, Elisabetta Leo, William C. Reinhold, Sudhir Varma, Alberto Ballestrero, James H. Doroshow, and Yves Pommier, “Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 37, pp. 15030–15035, 2012. View at Publisher · View at Google Scholar
  • Holly L Spraker, Shawn L Price, Aashi Chaturvedi, Joshua D Schiffman, Kevin B Jones, Stephen L Lessnick, Mary Beckerle, and R Lor Randall, “The clone wars - revenge of the metastatic rogue state: the sarcoma paradigm.,” Frontiers in oncology, vol. 2, pp. 2, 2012. View at Publisher · View at Google Scholar
  • Anna Raciborska, Katarzyna Bilska, Katarzyna Drabko, Radoslaw Chaber, Monika Pogorzala, Elżbieta Wyrobek, Katarzyna Polczyńska, Elżbieta Rogowska, Carlos Rodriguez-Galindo, and Wojciech Wozniak, “Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma,” Pediatric Blood & Cancer, 2013. View at Publisher · View at Google Scholar
  • Cormac Owens, Lesleigh S. Abbott, and Abha A. Gupta, “Optimal Management of Ewing Sarcoma Family of Tumors: Recent Developments in Systemic Therapy,” Pediatric Drugs, 2013. View at Publisher · View at Google Scholar
  • Patrick J. Grohar, and Lee J. Helman, “Prospects and challenges for the development of new therapies for Ewing sarcoma,” Pharmacology & Therapeutics, vol. 137, no. 2, pp. 216–224, 2013. View at Publisher · View at Google Scholar
  • Rawad Farhat, Hassan El-Solh, Nabil J. Khoury, Raya Saab, Roy Raad, Toufic Eid, Julien Feghaly, Samar Muwakkit, and Miguel Abboud, “Cyclophosphamide and Topotecan as First-line Salvage Therapy in Patients With Relapsed Ewing Sarcoma at a Single Institution,” Journal Of Pediatric Hematology Oncology, vol. 35, no. 5, pp. 356–360, 2013. View at Publisher · View at Google Scholar
  • Nilgun Kurucu, Neriman Sari, and Inci Ergurhan Ilhan, “Irinotecan and Temozolamide Treatment for Relapsed Ewing Sarcoma: A Single-Center Experience and Review of the Literature,” Pediatric Hematology And Oncology, vol. 32, no. 1, pp. 50–59, 2015. View at Publisher · View at Google Scholar
  • Nadège Corradini, and Françoise Redini, “New therapeutic targets in Ewing sarcoma: from pre-clinical proof-of-concept to clinical trials,” Bone Cancer, pp. 393–405, 2015. View at Publisher · View at Google Scholar
  • Maurizio D'Incalci, Lisa Turner, Carlos María Galmarini, Patrick J. Grohar, Nichole Maloney, Maria Jose Guillen Navarro, Susan M. Kitchen-Goosen, Elissa A. Boguslawski, Matt L. Harlow, Megan J. Bowman, Mary E. Winn, Galen Hostetter, Pablo M. Aviles, Joseph Roland, Matthew K. Easton, Zachary B. Madaj, and Ben K. Johnson, “Lurbinectedin inactivates the Ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus,” Cancer Research, vol. 76, no. 22, pp. 6657–6668, 2016. View at Publisher · View at Google Scholar
  • Lucia Martinez-Cruzado, Juan Tornin, Aida Rodriguez, Laura Santos, Eva Allonca, Maria Teresa Fernandez-Garcia, Aurora Astudillo, Juana Maria Garcia-Pedrero, and Rene Rodriguez, “Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models,” Neoplasia, vol. 19, no. 6, pp. 460–470, 2017. View at Publisher · View at Google Scholar
  • Kelly Bailey, Carrye Cost, Ian Davis, Julia Glade-Bender, Patrick Grohar, Peter Houghton, Michael Isakoff, Elizabeth Stewart, Nadia Laack, Jason Yustein, Damon Reed, Katherine Janeway, Richard Gorlick, Stephen Lessnick, Steven DuBois, and Pooja Hingorani, “Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force,” F1000Research, vol. 8, pp. 493, 2019. View at Publisher · View at Google Scholar